Indefinite Delivery Contract SPE2DU25D9119

The key details of this federal contract IDV are as follows:

The Defense Logistics Agency (DLA) awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, to provide a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide. The $499,999,999 IDC, valid through November 2026, covers an extensive portfolio of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications. This positions DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain, providing direct distribution of prescription drugs and pharmacy services to Department of Defense (DoD) healthcare sites.

The IDC was awarded under the DLA's upcoming Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) solicitation, which aims to establish multiple regional Prime Vendor Contracts to provide worldwide pharmaceutical support to various DoD customers, including the Defense Health Agency, United States Coast Guard, and U.S. Naval Fleet. The $30.3 billion PPV-G GEN V program is a firm-fixed price, requirements-type contract with a 30-month base period and three 30-month option periods, and will be awarded on a lowest price technically acceptable basis with the potential use of reverse auctions to obtain the best distribution fees.